European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha, The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol
July 21, 2015 at 07:03 AM EDT
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for Repatha™ (evolocumab), ...
